Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Rheumatology
•
Myositis
•
Dermatomyositis
•
Malignancy
How do you manage dermatomyositis related to underlying malignancy?
Is there a role of immunosuppression or treating underlying malignancy will be enough?
Answer from: at Academic Institution
Treat underlying malignancy with urgency Steroid + IVIG is the best treatment for dermatomyositis with active malignancy.
Sign In
or
Register
to read more
14848
Related Questions
For patients who do not have access to biologic therapies, what are some csDMARD combination pearls or tips that you have that have particular efficacy in different rheumatologic diseases?
How do you utilize tools such as MMT8 in clinical practice when evaluating myositis?
Is there a difference in efficacy between steroid-sparing agents like methotrexate, mycophenolate, and azathioprine in the treatment of immune-mediated myopathies?
How do you approach sequentially tapering combination therapy (i.e., IVIG, mycophenolate, rituximab) for dermatomyositis that is in remission?
How do you approach a patient with proximal lower limb asymmetrical weakness and pain of thighs, MRI findings of muscle enhancement of bilateral thighs but muscle biopsy with vasculitis changes only without findings of myositis.
How would you approach management of a patient with seropositive RA and UIP-ILD, with concern for active lung disease?
Do you consider immunosuppression in patients with a history of Sjogren's disease and clinical features of inclusion body myositis?
When stopping denosumab and transitioning to PO bisphosphonate, do you wait for 6 months after the last denosumab injection to start PO bisphosphonate?
How do you approach incidental NXP-2 antibody positivity in patients without current clinical evidence of myositis or systemic autoimmune disease?
How do you approach initial steroid dosing in patients with eosinophilic fasciitis?